SRX Global Says CERo Doses Seventh Patient in Phase 1/1b CER-1236 Trial

PUBT · 23h ago
SRX Global Says CERo Doses Seventh Patient in Phase 1/1b CER-1236 Trial
  • SRX Global updated its engineered T-cell strategy, highlighting pending acquisition target CERo's clinical-stage blood cancer therapy CER-1236.
  • CERo previously reported dosing its seventh patient in the Phase 1/1b CERTAIN-T trial on November 3, 2026.
  • Reported results showed no dose-limiting toxicities among previously treated second-cohort patients, with infused therapeutic cells expanding following administration.
  • The preliminary findings remain insufficient to establish CER-1236's safety or efficacy; the acquisition remains pending.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SRX Global Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611201258PRIMZONEFULLFEED9882333) on November 20, 2026, and is solely responsible for the information contained therein.